TherapeuticsMD, Inc.
TXMD
$1.10
$0.01991.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 306.84% | 25.56% | 32.87% | 1,132.08% | -46.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 306.84% | 25.56% | 32.87% | 1,132.08% | -46.45% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 306.84% | 25.56% | 32.87% | 1,132.08% | -46.45% |
| SG&A Expenses | -4.70% | -18.23% | -40.45% | -17.61% | -55.66% |
| Depreciation & Amortization | -46.67% | -28.57% | -84.30% | -26.15% | 40.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.05% | -19.18% | -53.67% | -18.26% | -51.43% |
| Operating Income | 72.94% | 31.44% | 80.63% | 51.55% | 52.31% |
| Income Before Tax | 151.90% | 17.43% | 105.24% | 60.46% | 56.50% |
| Income Tax Expenses | -- | -- | 27.91% | -- | -- |
| Earnings from Continuing Operations | 151.90% | 21.38% | 107.40% | 60.46% | 56.50% |
| Earnings from Discontinued Operations | 115.00% | -122.67% | -79.03% | 97.84% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 150.55% | 11.04% | 128.54% | 81.97% | 54.85% |
| EBIT | 72.94% | 31.44% | 80.63% | 51.55% | 52.31% |
| EBITDA | 77.68% | 31.81% | 85.45% | 53.59% | 57.36% |
| EPS Basic | 150.37% | 11.16% | 127.38% | 83.28% | 59.99% |
| Normalized Basic EPS | 157.89% | 28.31% | 29.88% | 63.37% | 107.72% |
| EPS Diluted | 150.37% | 3.30% | 126.16% | 83.02% | 60.63% |
| Normalized Diluted EPS | 157.89% | 28.31% | 29.88% | 63.37% | 107.72% |
| Average Basic Shares Outstanding | 0.36% | 0.17% | 4.45% | 7.77% | 12.85% |
| Average Diluted Shares Outstanding | 0.36% | 0.17% | 4.45% | 7.77% | 12.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |